Navigation Links
Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
Date:4/2/2011

aid (8%). Almost a third (31%) of the Medicare CDI hospital stays (initial or re-hospitalizations) included services in the intensive care unit (ICU) with an average length of stay in the ICU of 8.2 days. Almost two-thirds (62%) of the Medicare CDI hospital stays (initial or re-hospitalizations) included services in semi-private rooms with an average length of stay in semi-private rooms of 9.5 days.  We believe the study highlights the substantial economic burden of both acute and recurrent CDI. The dreaded outcomes – recurrence and death – are seen more commonly in the elderly and those with serious underlying diseases.

For a complete list of abstracts, please visit the Resources page on our website: www.optimerpharma.com

About Fidaxomicin

Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). In two Phase 3 trials for the treatment of CDI, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  Fidaxomicin also demonstrated statistically significant reduction in recurrences and an increase in global cure rate, defined as cure without recurrence. Importantly,  fidaxomicin reduced the risk of recurrence by 47% compared to vancomycin. The New England Journal of Medicine has published results from the first Phase 3 trial in an article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile Infection," which appeared in the February 3, 2011 issue.

About Clostridium difficile Infection (CDI)

Clostridium difficile infection (CDI), commonly referred to as "C. difficile" or "c-diff", has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each yea
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2. Juli 2015 BGI gab heute ... Hongkong vom American College of Pathologists (CAP) ... das erste klinische Next-Generation-Sequencing Labor, das in ... erhält und somit die höchsten Standards an ... US FDA - 21 CFR Part 11 ...
(Date:7/2/2015)... NORTH CHICAGO, Ill. , July 2, 2015 /PRNewswire/ ... 2015 financial results on Friday, July 24, 2015, before ... live webcast of the earnings conference call at 8 ... accessible through AbbVie,s Investor Relations website at www.abbvieinvestor.com ... available after 11 a.m. Central time. About ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Veterinary / Animal Vaccines ... to 2020" report to their offering. ... $7,197.9 Million by 2020 from $5,507.3 Million in 2015, ... Major factors fueling market growth are growing ...
Breaking Medicine Technology:BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2Veterinary / Animal Vaccines Market 2015 - Global Forecast to 2020 for the $7.19 Billion Industry 2
... FRANCISCO, Calif., March 25 Poniard Pharmaceuticals, Inc. (Nasdaq: ... oncology, today announced that it has reached its enrollment ... Picoplatin Efficacy After Relapse) trial. This global, pivotal Phase ... picoplatin in patients with recurrent small cell lung cancer ...
... AND EFFICACY FOR ROOM TEMPERATURE STORAGENANTONG CITY, China, ... SNBP) is pleased to announce that its patented ... relaxant marketed as Kutai in China, has successfully ... IV Clinical Study investigated the safety and effectiveness ...
Cached Medicine Technology:Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer 2Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer 3Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer 4Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing 2Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing 3
(Date:7/2/2015)... ... July 02, 2015 , ... Global leader and compression ... compression socks designed for men. , For style that’s quick on its feet, ... routine. This is great news for men everywhere because a simple change in socks ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... provides comprehensive information on the pipeline products with comparative analysis of the ... therapy (NPWT) with 22 market data tables and 4 figures, spread across ...
(Date:7/2/2015)... ... July 02, 2015 , ... Breakthrough ... wrist pain treatment. Dr. Lev Kalika, founder of New York Dynamic Neuromuscular ... authority on the conservative treatment of back, hip, knee and shoulder pain as ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Hand sanitizers have ... current summer flu season, according to fresh water advocate and radio host Sharon Kleyne, ... hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied correctly and ...
(Date:7/2/2015)... ... July 02, 2015 , ... The report summarizes key statistics ... report is a valuable source of guidance and direction for companies and individuals ... for the Gelatin Capsule industry including capacity, production, production value, cost and profit, ...
Breaking Medicine News(10 mins):Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4
... Farms, a national,ground beef producer, is issuing a voluntary ... N.Y., facility and sold through Price,Chopper, Shaw,s, BJ,s, and ... affected product may contain small pieces of hard plastic. ... 05/15/08, or a,"Julian date 124" on the package,s label. ...
... 12 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... 2008., The net loss for the first quarter ... million during the same period in 2007. As of,March ... investments of $81.1 million., First Quarter Financial Results, ...
... prevented heart failure in those with Duchenne muscular dystrophy ... Duchenne muscular dystrophy often suffer from heart failure, but ... condition, a new Canadian study finds. , In experiments ... performance by preventing the breakdown of a compound called ...
... WASHINGTON, May 12 Most baby boomers say,they ... to a,new survey conducted by Harris Interactive on ... would have difficulty paying bills and,many would have ... disability,occurred., (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), ...
... Effective May 19, the Texas,Hospital Association will have a ... 1108 Lavaca, located within steps of the Texas Capitol., ... Association,and a group of investors, THA was able to ... our members," said Dan Stultz, M.D., FACP, FACHE,president/CEO of ...
... MONTREAL, May 12 /PRNewswire-FirstCall/ - CryoCath(R) Technologies,Inc., the ... announced financial results for the second quarter,ended March 31, ... Highlights:, - Accelerated revenue growth in ... increase over comparable electrophysiology (EP) ...
Cached Medicine News:Health News:Fairbank Farms Issues Voluntary Recall for Selected Ground Beef Products 2Health News:MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results 2Health News:MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results 3Health News:MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results 4Health News:MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results 5Health News:Viagra May Protect Hearts of Some Muscular Dystrophy Patients 2Health News:Most Baby Boomers are Financially Unprepared for a Potential Disability 2Health News:Hospital Association Moves Headquarters to Downtown Austin 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 12
... Airial Handheld Ultrasonic Nebulizer has ... This compact, portable, and lightweight ... fast & quite treatments operating ... or DC auto adapter. , ...
With ten colors available, Spectrums line of Color-Coded Fiberoptic Light Cables makes it easy to track by department....
Lumitex® LightMat® Surgical Illuminator improves visualization in deep cavity surgery. Flexible and malleable, it attaches easily to most retractors, bringing bright, cool area lighting where...
... the exceptional performance you need at a price ... and durability youd expect from headlights priced much ... features our thinnest cable and adjusts from 90 ... when you reach for a headlight you can ...
Medicine Products: